| 2024-04-23 10:17 | CC:RVV | Revive Therapeutics Ltd | 0.025 | News Release200 | Revive receives Bucillamine FDA Type C meeting approval |
| 2024-04-18 10:56 | CC:RVV | Revive Therapeutics Ltd | 0.025 | News Release200 | Revive gets FDA acceptance for meeting request |
| 2024-04-02 11:21 | CC:RVV | Revive Therapeutics Ltd | 0.03 | News Release200 | Revive clinical study enrolls nearly 50% of sample |
| 2024-03-27 13:25 | CC:RVV | Revive Therapeutics Ltd | | News Release200 | Revive submits meeting request to U.S. FDA |
| 2024-03-19 10:11 | CC:RVV | Revive Therapeutics Ltd | 0.03 | News Release200 | Revive receives notice to submit Type C meeting request |
| 2024-03-12 09:42 | CC:RVV | Revive Therapeutics Ltd | 0.035 | News Release200 | Revive recaps work on bucillamine, long COVID product |
| 2024-02-28 18:51 | CC:RVV | Revive Therapeutics Ltd | 0.025 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2024-02-28 18:51 | CC:RVV | Revive Therapeutics Ltd | 0.025 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2024-02-26 16:24 | CC:RVV | Revive Therapeutics Ltd | 0.025 | News Release200 | Revive Therapeutics closes $1.18M final tranche |
| 2024-02-01 11:25 | CC:RVV | Revive Therapeutics Ltd | 0.03 | News Release200 | Revive proposes phase 2/3 bucillamine clinical study |
| 2024-01-31 17:24 | CC:RVV | Revive Therapeutics Ltd | 0.025 | News Release200 | Revive closes $913,500 first tranche of placement |
| 2024-01-24 18:00 | CC:RVV | Revive Therapeutics Ltd | 0.04 | News Release200 | Revive arranges $3-million private placement |
| 2024-01-16 11:28 | CC:RVV | Revive Therapeutics Ltd | 0.035 | News Release200 | Revive talks Bucillamine for nerve agent exposure |
| 2024-01-10 10:07 | CC:RVV | Revive Therapeutics Ltd | 0.035 | News Release200 | Revive develops new bucillamine formulation |
| 2023-12-20 13:11 | CC:RVV | Revive Therapeutics Ltd | 0.03 | News Release200 | Revive shareholders approve all matters at AGSM |
| 2023-12-18 10:14 | CC:RVV | Revive Therapeutics Ltd | 0.03 | News Release200 | Revive, Attwill to develop Bucillamine formulation |
| 2023-11-29 19:43 | CC:RVV | Revive Therapeutics Ltd | 0.03 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2023-11-29 19:28 | CC:RVV | Revive Therapeutics Ltd | 0.03 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2023-11-21 12:18 | CC:RVV | Revive Therapeutics Ltd | 0.03 | News Release200 | Revive expects to complete bucillamine work by year-end |
| 2023-11-06 10:30 | CC:RVV | Revive Therapeutics Ltd | 0.03 | News Release200 | Revive unit, Lawson Health to develop long COVID tests |
| 2023-10-27 21:18 | CC:RVV | Revive Therapeutics Ltd | 0.03 | SEDAR MD & A815 | SEDAR MD & A |
| 2023-10-27 21:13 | CC:RVV | Revive Therapeutics Ltd | 0.03 | SEDAR Audited Annual Financial Statements804 | SEDAR Audited Annual Financial Statements |
| 2023-10-17 10:09 | CC:RVV | Revive Therapeutics Ltd | 0.03 | News Release200 | Revive, DRDC to study bucillamine for nerve agents |
| 2023-10-11 15:43 | CC:RVV | Revive Therapeutics Ltd | 0.03 | News Release200 | Revive hopes to finish bucillamine development by Dec. |
| 2023-08-22 11:17 | CC:RVV | Revive Therapeutics Ltd | 0.045 | News Release200 | Revive begins developing bucillamine formulation |
| 2023-07-28 09:31 | CC:RVV | Revive Therapeutics Ltd | 0.035 | News Release200 | Revive Therapeutics files patent for bucillamine |
| 2023-07-06 09:06 | CC:RVV | Revive Therapeutics Ltd | 0.03 | News Release200 | Revive study fails to achieve statistical significance |
| 2023-05-30 20:55 | CC:RVV | Revive Therapeutics Ltd | 0.055 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2023-05-30 20:55 | CC:RVV | Revive Therapeutics Ltd | 0.055 | SEDAR MD & A815 | SEDAR MD & A |
| 2023-05-30 09:43 | CC:RVV | Revive Therapeutics Ltd | 0.055 | News Release200 | Revive begins evaluating bucillamine study data |
| 2023-05-12 09:15 | CC:RVV | Revive Therapeutics Ltd | 0.07 | News Release200 | Revive Therapeutics halts bucillamine COVID-19 trial |